Lymphoma - A Therapeutic & Competitive Insight

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 Table of Contents
4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables

5 Introduction
5.1 Disease Definition
5.2 Etiology & Pathophysiology
5.3 Epidemiology

6 Current Treatment Strategies
6.1 Hodgkin’s Disease
6.1.1 Radiation Therapy
6.1.2 Chemotherapy
6.1.3 Transplantation
6.1.4 Treatment Option Overview
6.2 Non-Hodgkin’s Lymphoma
6.2.1 Radiation Therapy
6.2.2 Chemotherapy
6.2.3 Immunotherapy
6.2.4 Bone Marrow and Peripheral Blood Transplants
6.2.5 Watch and Wait
6.2.6 Treatment Option Overview
6.3 Prognosis
6.3.1 Hodgkin’s Disease
6.3.2 Non-Hodgkin

7 Progress in Current Treatment Strategies
7.1 HODGKIN
7.2 NON-HODGKIN
7.3 Rituxan
7.4 Bexxar
7.5 Zevalin

8 Key Therapeutic Strategies
8.1 Antibodies & Immunostimulation
8.2 Small molecules: Apoptosis inducers & Kinase inhibitors

9 Competitive Landscape in Drug Development: The Late Stage Pipeline

10 Current Drug Development: The Early Stage Pipeline

11 Disclaimer
11.1 Liability
11.2 Completeness

12 Appendix 1: Selected Companies – Anticancer Pipelines
12.1 Accentia BioPharmaceuticals
12.2 Biogen Idec
12.3 Cell Therapeutics
12.4 Cephalon
12.5 Chiron Corporation (Now Novartis)
12.6 Eli Lilly
12.7 Favrille
12.8 Genentech
12.9 Genitope Corporation
12.10 Genmab
12.11 Genta
12.12 GlaxoSmithKline
12.13 Immunomedics
12.14 Inex Pharmaceuticals
12.15 Millennium Pharmaceuticals
12.16 Protein Design Labs
12.17 Roche
12.18 Sanofi-Aventis
12.19 Seattle Genetics
12.20 Wyeth
Company & Drug Index

4.1 List of Boxes
Box 1 Possible Complications of Treatment
Box 2 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 3 Subclassification of Stage
Box 4 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 5 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
Box 6 Staging subclassification system
Box 7 Study details

4.2 List of Figures
Figure 1: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.

4.3 List of Tables
Table 1 Drugs used in the treatment of lymphoma.
Table 2 Summary of Strategies Enhancing Antibody Function
Table 3 Cancer immunotherapy strategies.
Table 4 Protein Kinase Targets in Clinical Trials for Lymphoma
Table 5 Recent published studies Aldesleukin
Table 6 Recent published studies Arsenic trioxide
Table 7 Recent published studies BiovaxID
Table 8 Recent published studies Bortezomib
Table 9 Recent published studies epratuzumab
Table 10 Recent published studies FavId
Table 11 Recent published studies MyVax
Table 12 Recent published studies Nelarabine
Table 13 Recent published studies Genasense
Table 14 Recent published studies Pixantrone
Table 15 Recent published studies temsirolimus
Table 16 Recent published studies Zanolimumab
Table 17 Recent published studies Flavopiridol
Table 18 Recent published studies bevacizumab
Table 19 Recent published studies CMC-544
Table 20 Recent published studies galiximab
Table 21 Recent published studies LY317615
Table 22 Recent published studies SGN-40
Table 23 Recent published studies Apolizumab
Table 24 Recent published studies SGN-30
Table 25 Accentia BioPharmaceuticals’ Anticancer Pipeline
Table 26 Biogen-Idec’s Anticancer Pipeline
Table 27 Cell Therapeutics’ Anticancer Pipeline
Table 28 Cephalon’s Anticancer Pipeline
Table 29 Chiron´s Anticancer Pipeline
Table 30 Eli Lilly’s Anticancer Pipeline
Table 31 Favrille anticancer pipeline
Table 32 Genentech’s Anticancer Pipeline
Table 33Genitope’s Anticancer Pipeline
Table 34 Genmab’s Anticancer Pipeline
Table 35 Genta’s Anticancer Pipeline
Table 36 GlaxoSmithKline’s Anticancer Pipeline
Table 37 Immunomedics’ Anticancer Pipeline
Table 38 Inex Pharmaceuticals’ Anticancer Pipeline
Table 39 Millennium Pharmaceuticals’ Anticancer Pipeline
Table 40 Protein Design Labs’ Anticancer Pipeline
Table 41 Roche’s Anticancer Pipeline
Table 42 Sanofi-Aventis anticancer pipeline
Table 43 Seattle Genetics’ Anticancer Pipeline
Table 44 Wyeth’s Anticancer Pipeline